An Approval That Fills a Longstanding Treatment Gap
The Food and Drug Administration has approved Imaavy, known generically as nipocalimab-aahu, for warm autoimmune hemolytic anemia in adults and children 12 and older who are currently being treated with corticosteroids or have previously been treated with corticosteroids. It is the first therapy proven safe and effective specifically for the condition.
Johnson and Johnson, which developed the drug, announced the approval following an FDA priority review granted in April. It is the second approved use for the drug, which was cleared for generalized myasthenia gravis in April 2025. The prescribing information now covers both conditions.
Warm autoimmune hemolytic anemia occurs when the immune system produces antibodies that bind to red blood cells, marking them for destruction and causing anemia and severe fatigue. Until now, treatment meant borrowing therapies developed for other conditions. Patients typically started on corticosteroids, then moved through immunosuppressive drugs, spleen removal, or transfusions when steroids failed or when the side effects of long-term steroid use became intolerable. None of those options were tested and approved for this disease. Karen Jones, president and executive director of the patient group wAIHA Warriors, said in the company announcement that "for the first time, our community has a treatment specifically for our disease."
Inside the Trial Numbers
The approval rests on the ENERGY trial, a multicenter, randomized, double blind, placebo-controlled Phase 2 and 3 study registered on ClinicalTrials.gov. It randomized 115 adults roughly evenly across two nipocalimab dosing schedules and placebo.
The primary endpoint was a durable hemoglobin response, defined strictly as reaching a hemoglobin level of at least 10 grams per deciliter, with an increase of at least 2 grams per deciliter from baseline, maintained for at least 28 days and without rescue therapy. Among patients receiving the approved dose, 23.7 percent achieved that response, compared with 7.7 percent on placebo.
Read carefully: that is a genuine improvement and also a limitation worth stating plainly. Roughly three times as many treated patients reached the bar as placebo patients. But roughly three quarters of treated patients did not reach it. This is a meaningful new option, not a solution for everyone with the condition.
Two secondary findings are relevant to daily life. Treated patients showed a mean hemoglobin increase of about 1 g/dL within the first week, and among those who responded, the median time to first response was 4.1 weeks, compared with 12.1 weeks on placebo. On a standard fatigue questionnaire, the treated group improved by an average of 3.51 points more than the placebo group at 24 weeks, with a confidence interval ranging from 0.64 to 6.39. The company notes that both results are considered descriptive under the trial's prespecified statistical plan, meaning they should be treated as supportive rather than definitive.
Safety in this population matched what has already been observed with the drug in myasthenia gravis, with no new signals identified. The most common adverse reactions were swelling in the hands, ankles, or feet, diarrhea, and fever. Because the drug works by lowering circulating antibodies, infection risk is an expected consideration that prescribing clinicians monitor.
Two disclosures accompany these numbers. The trial was conducted and reported by the manufacturer, and David Kuter of Massachusetts General Hospital, the physician quoted in the company announcement, has served as a consultant to Johnson and Johnson.
The Patients Most Likely to Be Affected
This is a rare disease. Roughly 1 to 3 people per 100,000 are newly affected each year, and about 1 in 8,000 people are living with it. It affects both women and men, at any age, with incidence rising after 50.
The people most likely to benefit are those who have already cycled through steroids without durable improvement, or who are living with the accumulated effects of long-term corticosteroid use, which can include bone loss, elevated blood sugar, weight gain, mood changes, and increased infection risk. For those patients, an approved therapy that targets the antibodies driving the disease represents a different mechanism rather than another version of broad immune suppression.
The burden of this condition is often underestimated because anemia sounds routine. It is not. Patient organizations and the underlying literature describe elevated risks of blood clots in the veins, acute kidney failure, and serious infection. The fatigue is disabling rather than inconvenient, and the relapsing pattern means patients can improve, return to work or school, and then lose that ground when hemoglobin drops again.
The drug is given as an intravenous infusion at 30 milligrams per kilogram every four weeks. That schedule means regular infusion center visits, which carry their own costs in time, travel, and time away from work. It is also worth noting that the pivotal trial enrolled adults, while the approval extends to patients as young as 12.
Cost and Access Questions Still Open
Johnson and Johnson has not published a list price for this use, and no coverage policies from commercial insurers, Medicare, or Medicaid have been announced. For an infused biologic, coverage typically falls under a plan's medical benefit rather than the pharmacy benefit, which usually requires prior authorization and often results in coinsurance based on a percentage of cost rather than a flat copay.
Patients should expect that process to take time. Practical steps include asking the prescribing hematologist's office who handles prior authorization, requesting a written benefits verification before the first infusion, and asking specifically whether the infusion site is in-network, since the site of care can substantially change out-of-pocket costs. The company says its patient support program offers educational resources, a dedicated nurse navigator, and cost-support options regardless of insurance type, though federal rules limit the forms of financial assistance available to people with government coverage.
Nobody currently taking corticosteroids or other therapy for this condition should change or stop treatment based on this approval. Any transition is a decision for a treating hematologist.
Several questions remain unanswered. Long-term outcomes beyond the trial period are unknown. Whether the drug works in patients who have already failed multiple other therapies has not been separately established. And how quickly insurers will cover it is unclear. Patient advocacy organizations focused on the condition are likely to be the fastest source of practical coverage information as policies are published.
Key Questions Answered
What was approved? Imaavy, generically nipocalimab-aahu, for warm autoimmune hemolytic anemia in adults and children 12 and older who are currently or were previously treated with corticosteroids.
Why is this described as a first? No therapy had previously been proven safe and effective specifically for this disease. Patients were managed with steroids and other options borrowed from different conditions.
How well did it work? In the ENERGY trial, 23.7 percent of treated patients achieved a durable hemoglobin response, compared with 7.7 percent on placebo, indicating that most treated patients did not reach that endpoint.
How is it given? As an intravenous infusion at 30 milligrams per kilogram every four weeks.
Who has this condition? Roughly one to three people per 100,000 are newly affected each year. It affects both women and men at any age, with incidence increasing after 50.
Will insurance cover it? No coverage policies have been announced. Infused biologics typically require prior authorization under a plan's medical benefit.
Should current patients change treatment now? No. Any change to an existing regimen should be decided in consultation with the treating hematologist.
